{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:51:57Z","timestamp":1783612317444,"version":"3.55.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) clearance are associated with an improved prognosis in chronic hepatitis B (CHB) patients. These end points are more often achieved with a one-year course of pegylated interferon (PEG-IFN) compared with one year of nucleoside\/nucleotide analogue therapy. However, prolonged nucleoside\/nucleotide analogue therapy may result in comparable serological response rates as with PEG-IFN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared serological and virological response rates among HBeAg-positive CHB patients treated with long-term continuous entecavir (ETV; n=91) for a median of 92 (IQR 50\u2013132) weeks or one year of PEG-IFN ( n=266) with comparable follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median follow-up was 92 weeks (IQR 78\u2013198) for patients treated with PEG-IFN and 92 weeks (IQR 50\u2013132) for patients treated with ETV. Finite PEG-IFN therapy resulted in significantly higher rates of HBeAg seroconversion (adjusted hazard ratio [HR] 3.16; P&lt;0.001) and HBsAg clearance (HR 5.66; P=0.027) when compared to prolonged ETV treatment, whereas, ETV resulted in higher rates of HBV DNA undetectability (OR 31.14; P&lt;0.001) also after adjustment for HBV genotype and other relevant baseline factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study shows that finite PEG-IFN is associated with a higher probability of serological, but not virological, response for HBeAg-positive CHB patients when compared to prolonged ETV, even after correction for baseline differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp2319","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T08:53:26Z","timestamp":1345107206000},"page":"1605-1608","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir"],"prefix":"10.1177","volume":"17","author":[{"given":"Milan J","family":"Sonneveld","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland","family":"Zoutendijk","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands"},{"name":"Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry LA","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,11,1]]},"reference":[{"key":"bibr1-IMP2319","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"bibr2-IMP2319","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60207-5"},{"key":"bibr3-IMP2319","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801644"},{"key":"bibr4-IMP2319","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013215"},{"key":"bibr5-IMP2319","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20128"},{"key":"bibr6-IMP2319","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605303342202"},{"key":"bibr7-IMP2319","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"bibr8-IMP2319","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"bibr9-IMP2319","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.031"},{"key":"bibr10-IMP2319","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02384.x"},{"key":"bibr11-IMP2319","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2003.08.015"},{"key":"bibr12-IMP2319","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.011"},{"key":"bibr13-IMP2319","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"bibr14-IMP2319","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23568"},{"key":"bibr15-IMP2319","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.03.059"},{"key":"bibr16-IMP2319","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"bibr17-IMP2319","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21513"},{"key":"bibr18-IMP2319","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.014"},{"key":"bibr19-IMP2319","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.07.046"},{"key":"bibr20-IMP2319","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23844"},{"key":"bibr21-IMP2319","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301096"},{"key":"bibr22-IMP2319","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.061"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:51:03Z","timestamp":1777380663000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP2319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.3851\/IMP2319"],"URL":"https:\/\/doi.org\/10.3851\/imp2319","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}